Pharmafile Logo
Pharmafocus logo
Advanced Search

bristol myers-squibb

Showing 6 posts of 6 posts found.

nektar-therapeutics

“Underwhelming” drug data devastates Nektar, shares fall by 42%

June 5, 2018
Manufacturing and Production, Research and Development ASCO, BMS, Bristol-Myers Squibb, Cancer, Nektar, bristol myers-squibb, pharma

Nektar Therapeutics has seen its share price devastated after revealing disappointing trial data for its candidate NKTR-214 in combination with …

News
joe_biden_and_obama

New formulary ‘bank’ to aid research into combination therapies

January 11, 2017
Medical Communications, Research and Development 21st Century Cures Act, Bristol-Myers Squibb, Eli Lilly, Joe Biden, Obama, bristol myers-squibb, combination therapy

As part of the wider ‘cancer moonshot’ initiative, confirmed by the signing of the 21st Century Cures Act by Obama, …

News
giovanni_caforio

Giovanni Caforio to be made chairman of the board at BMS

January 3, 2017
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bristol-Myers Squibb, Giovanni Caforio, bristol myers-squibb

Bristol-Myers Squibb has announced that Giovanni Caforio has been appointed chairman of the board. Caforio will take up the position …

Appointment
bristol

Opdivo first PD-1 inhibitor given European approval for haematological cancer

November 25, 2016
Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, EMA, PD1-Inhibitor, bristol myers-squibb

Bristol-Myers Squibb announced that it has received the first and only European approval for a PD1 inhibitor in the treatment …

News
BMS image

BMS lung cancer drug scores in Phase II

October 31, 2014
Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, FDA, NSCLC, bristol myers-squibb, odivo

Bristol-Myers Squibb is still in the hunt to gain significant market share in the PD-1 therapeutic vaccine race after releasing …

News
BMS image

BMS therapeutic cancer vaccine given swift FDA appraisal

September 29, 2014
Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, FDA, Vaccine, bristol myers-squibb, keytruda, melanoma, opdivo

Bristol-Myers Squibb has been granted a speedy review for its new cancer immunotherapy drug Opdivo by the FDA for patients …

News

Latest content

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024

Neurolentech and Kaerus Bioscience enter partnership for research on neurodevelopmental disorder

April 22, 2024

Ardena announces €20m expansion following first GMP approval

April 19, 2024